ClinicalTrials.gg
CompletedNCT01114880Updated Dec 1, 2011Results posted

Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

A Phase 3 interventional study of adalimumab and placebo in Ankylosing Spondylitis, sponsored by Abbott. Completed at 9 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-12-01.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing adalimumab in Spondylitis, Ankylosing — 2 open to participants now, 3 under way, none of them phase 3. Adalimumab · Spondylitis, Ankylosing.

Enrollment
4th of 19
344 · median 80
Started
2010
with 1 other
Phase 3
7 of 19
none open now
Registered
7th of 19
by date
Lead sponsor
5 of 19
Abbott

Among the 19 studies testing adalimumab in Spondylitis, Ankylosing, this one is the 4th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 7th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 98 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

2 of the 19 studies testing adalimumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing adalimumab in Spondylitis, Ankylosing, or all of them as a file.
02

Study summary

Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory drugs (NSAIDs)

Read the detailed description

Adults with active ankylosing spondylitis (AS) were randomized in a 2:1 ratio to receive treatment with adalimumab 40 mg every other week (eow) or matching placebo, given subcutaneously (SC), in the 12-week double-blind (DB) phase. Randomized participants received one SC injection of the appropriate DB study medication (adalimumab 40 mg or matching placebo) at Week 0 and then eow until Week 10. Participants who completed the DB phase could enter the 12-week open-label (OL) phase, during which all participants received treatment with adalimumab 40 mg eow, starting at Weeks 12 through 22. No study drug was administered or injected at the final study visit (Week 24). A follow-up visit occurred 70 days after the last dose of study drug (in DB or OL phases) to obtain information on any ongoing or new adverse events (AEs).

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • ankylosing spondylitis
  • China
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 through 65 years
  • Has a diagnosis of ankylosing spondylitis (AS) based on the Modified New York Criteria
  • Has active AS, as defined by fulfillment of at least 2 of the following 3 conditions at both Screening and Baseline visits:

    • BASDAI score at least 4 cm
    • Total back pain on a visual analog scale (VAS) at least 40 mm
    • Morning stiffness at least 1 hr
  • Has inadequate response to or intolerance to one or more non-steroidal anti-inflammatory drugs (NSAIDs) as defined by the Investigator

Exclusion criteria

Exclusion Criteria:

  • Has total spinal ankylosis (bamboo spine)
  • Has undergone spinal surgery or joint surgery involving joints assessed within 2 months prior to Baseline
  • Has extra-articular manifestations (i.e., psoriasis, uveitis, inflammatory bowel disease) that is not clinically stable, as defined by the Investigator's best clinical judgment, for at least 28 days prior to Baseline
  • Has received intra-articular joint injection(s), spinal or paraspinal injection(s) with within 28 days prior to Baseline
  • Has prior exposure to any biologic therapy with potential therapeutic impact on AS, including anti-TNF (tumor necrosis factor) therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
344 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Blinded placebo from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.

    Biological: adalimumab · Other: placebo

  • Experimental
    Adalimumab

    Blinded adalimumab from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week

    Also known as: ABT-D2E7, Humira

  • Otherplacebo

    Prefilled syringe, matching placebo administered subcutaneously every other week

06

What researchers measure

Primary outcomes

  1. Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria

    ASAS20 responder had improvement of 20% or more and absolute improvement of at least 10 units (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the following 4 domains, with absence of deterioration (change for worse of at least 20% and net worsening of at least 10 units) in the potential remaining domain: Patient's Global Assessment of Disease Activity; Total Back Pain visual analog scale (VAS); Bath Ankylosing Spondylitis Functional Index (BASFI); and Inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).

    Time frame: Week 12

Secondary outcomes

  1. Number of Participants Meeting the ASAS20 Response Criteria

    ASAS20 responder had improvement of 20% or more and absolute improvement of at least 10 units (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the following 4 domains, with absence of deterioration (change for worse of at least 20% and net worsening of at least 10 units) in the potential remaining domain: Patient's Global Assessment of Disease Activity; Total Back Pain visual analog scale (VAS); Bath Ankylosing Spondylitis Functional Index (BASFI); and Inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).

    Time frame: Week 24

  2. Number of Participants Meeting the ASAS40 Response Criteria

    An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).

    Time frame: Week 12

  3. Number of Participants Meeting the ASAS40 Response Criteria

    An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).

    Time frame: Week 24

  4. Number of Participants Meeting the ASAS5/6 Response Criteria

    An ASAS5/6 responder had an improvement from Baseline of 20% or more in 5 of the following 6 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores); spinal mobility (lateral lumbar flexion from Bath Ankylosing Spondylitis Metrology Index \[BASMI\]); and acute phase reactant (high-sensitivity C-reactive protein).

    Time frame: Week 12

  5. Number of Participants Meeting the ASAS5/6 Response Criteria

    An ASAS5/6 responder had an improvement from Baseline of 20% or more in 5 of the following 6 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores); spinal mobility (lateral lumbar flexion from Bath Ankylosing Spondylitis Metrology Index \[BASMI\]); and acute phase reactant (high-sensitivity C-reactive protein).

    Time frame: Week 24

  6. Number of Participants With ASAS Partial Remission

    Participants were classified as having achieved ASAS partial remission if they had a value of less than 20 on a scale from 0 (normal/none) to 100 (most severe) in each of 4 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); and inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).

    Time frame: Week 12

  7. Number of Participants With ASAS Partial Remission

    Participants were classified as having achieved ASAS partial remission if they had a value of less than 20 on a scale from 0 (normal/none) to 100 (most severe) in each of 4 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); and inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).

    Time frame: Week 24

  8. Change From Baseline in Patient Global Assessment of Disease Activity

    Participants assessed their disease activity during the preceding week using a 100 millimeter (mm) visual analog scale, with responses ranging from no activity (0) to severe activity (100).

    Time frame: Baseline and Week 12

  9. Change From Baseline in Patient Global Assessment of Disease Activity

    Participants assessed their disease activity during the preceding week using a 100 millimeter (mm) visual analog scale, with responses ranging from no activity (0) to severe activity (100).

    Time frame: Baseline and Week 24

  10. Change From Baseline in Total Back Pain Score

    Participants assessed their total back pain within the preceding week using a total back pain 100 mm visual analog scale, with responses ranging from no pain (0) to most severe pain (100).

    Time frame: Baseline and Week 12

  11. Change From Baseline in Total Back Pain Score

    Participants assessed their total back pain within the preceding week using a total back pain 100 mm visual analog scale, with responses ranging from no pain (0) to most severe pain (100).

    Time frame: Baseline and Week 24

  12. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score

    Participants assessed their ability to perform 10 selected activities (e.g., putting on socks or tights without help or aids, bending forward from the waist to pick up a pen from the floor without an aid) during the preceding week. Responses ranged from 0 (easy) to 100 (impossible). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 100.

    Time frame: Baseline and Week 12

  13. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score

    Participants assessed their ability to perform 10 selected activities (e.g., putting on socks or tights without help or aids, bending forward from the waist to pick up a pen from the floor without an aid) during the preceding week. Responses ranged from 0 (easy) to 100 (impossible). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 100.

    Time frame: Baseline and Week 24

  14. Change From Baseline in Inflammation Score

    The Inflammation score is the mean of the 10-cm visual analog scale scores from the 2 morning stiffness-related BASDAI questions: "How would you describe the overall level of morning stiffness you have had from the time you wake up?", with response ranging from none to very severe; and "How long does your morning stiffness last from the time you wake up?", with response ranging from 0 hours to 2 or more hours.

    Time frame: Baseline and Week 12

  15. Change From Baseline in Inflammation Score

    The Inflammation score is the mean of the 10-cm visual analog scale scores from the 2 morning stiffness-related BASDAI questions: "How would you describe the overall level of morning stiffness you have had from the time you wake up?", with response ranging from none to very severe; and "How long does your morning stiffness last from the time you wake up?", with response ranging from 0 hours to 2 or more hours.

    Time frame: Baseline and Week 24

  16. Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria

    A BASDAI50 responder had at least a 50% improvement from Baseline in BASDAI score. In the BASDAI, participants use a 10-centimeter visual analog scale to answer 6 questions pertaining to symptoms experienced in the preceding week (e.g., How would you describe the overall level of fatigue/tiredness you have experienced? How long does your morning stiffness last from the time you wake up?) Responses range from "none" to "very severe" or from 0 hours to 2 or more hours for morning stiffness. The score is calculated as 0.2 (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2).

    Time frame: Week 12

  17. Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria

    A BASDAI50 responder had at least a 50% improvement from Baseline in BASDAI score. In the BASDAI, participants use a 10-centimeter visual analog scale to answer 6 questions pertaining to symptoms experienced in the preceding week (e.g., How would you describe the overall level of fatigue/tiredness you have experienced? How long does your morning stiffness last from the time you wake up?) Responses range from "none" to "very severe" or from 0 hours to 2 or more hours for morning stiffness. The score is calculated as 0.2 (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2).

    Time frame: Week 24

  18. Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)

    Elevation of hs-CRP is a nonspecific marker of inflammation. Values above 5 milligrams/liter (mg/L) were considered abnormally high. Decrease in level of hs-CRP indicates reduction in inflammation.

    Time frame: Baseline and Week 12

  19. Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)

    Elevation of hs-CRP is a nonspecific marker of inflammation. Values above 5 milligrams/liter (mg/L) were considered abnormally high. Decrease in level of hs-CRP indicates reduction in inflammation.

    Time frame: Baseline and Week 24

  20. Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score

    The SF-36 questionnaire, version 2, consists of 36 general health questions with 2 components, physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.

    Time frame: Baseline and Week 12

  21. Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score

    The SF-36 questionnaire, version 2, consists of 36 general health questions with 2 components, physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.

    Time frame: Baseline and Week 24

07

Results

Posted Nov 4, 2011

Participant flow

Period 1 (Week 0 to Week 12)
Participant flow — Period 1 (Week 0 to Week 12)
MilestoneAdalimumabPlacebo
Started229115
Completed224113
Not completed52
Withdrew: Adverse event40
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up01
Withdrew: Poor subject compliance01
Period 2 (Week 12 to Week 24)
Participant flow — Period 2 (Week 12 to Week 24)
MilestoneAdalimumabPlacebo
Started224113
Completed221111
Not completed32
Withdrew: Adverse event30
Withdrew: Lost to follow-up02

Outcome measures

PrimaryNumber of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria

ASAS20 responder had improvement of 20% or more and absolute improvement of at least 10 units (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the following 4 domains, with absence of deterioration (change for worse of at least 20% and net worsening of at least 10 units) in the potential remaining domain: Patient's Global Assessment of Disease Activity; Total Back Pain visual analog scale (VAS); Bath Ankylosing Spondylitis Functional Index (BASFI); and Inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria
participantsAdalimumab/AdalimumabPlacebo/Adalimumab
Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria15435
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · Chi-squared · p = < 0.001
SecondaryNumber of Participants Meeting the ASAS20 Response Criteria

ASAS20 responder had improvement of 20% or more and absolute improvement of at least 10 units (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the following 4 domains, with absence of deterioration (change for worse of at least 20% and net worsening of at least 10 units) in the potential remaining domain: Patient's Global Assessment of Disease Activity; Total Back Pain visual analog scale (VAS); Bath Ankylosing Spondylitis Functional Index (BASFI); and Inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants Meeting the ASAS20 Response Criteria
participantsAdalimumab/AdalimumabPlacebo/Adalimumab
Number of Participants Meeting the ASAS20 Response Criteria18085
SecondaryNumber of Participants Meeting the ASAS40 Response Criteria

An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants Meeting the ASAS40 Response Criteria
participantsAdalimumab/AdalimumabPlacebo/Adalimumab
Number of Participants Meeting the ASAS40 Response Criteria10211
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · Chi-squared · p = < 0.001
SecondaryNumber of Participants Meeting the ASAS40 Response Criteria

An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants Meeting the ASAS40 Response Criteria
participantsAdalimumab/AdalimumabPlacebo/Adalimumab
Number of Participants Meeting the ASAS40 Response Criteria13463
SecondaryNumber of Participants Meeting the ASAS5/6 Response Criteria

An ASAS5/6 responder had an improvement from Baseline of 20% or more in 5 of the following 6 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores); spinal mobility (lateral lumbar flexion from Bath Ankylosing Spondylitis Metrology Index \[BASMI\]); and acute phase reactant (high-sensitivity C-reactive protein).

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants Meeting the ASAS5/6 Response Criteria
participantsAdalimumab/AdalimumabPlacebo/Adalimumab
Number of Participants Meeting the ASAS5/6 Response Criteria12814
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · Chi-squared · p = < 0.001
SecondaryNumber of Participants Meeting the ASAS5/6 Response Criteria

An ASAS5/6 responder had an improvement from Baseline of 20% or more in 5 of the following 6 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores); spinal mobility (lateral lumbar flexion from Bath Ankylosing Spondylitis Metrology Index \[BASMI\]); and acute phase reactant (high-sensitivity C-reactive protein).

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants Meeting the ASAS5/6 Response Criteria
participantsAdalimumab/AdalimumabPlacebo/Adalimumab
Number of Participants Meeting the ASAS5/6 Response Criteria15069
SecondaryNumber of Participants With ASAS Partial Remission

Participants were classified as having achieved ASAS partial remission if they had a value of less than 20 on a scale from 0 (normal/none) to 100 (most severe) in each of 4 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); and inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With ASAS Partial Remission
participantsAdalimumab/AdalimumabPlacebo/Adalimumab
Number of Participants With ASAS Partial Remission504
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · Chi-squared · p = < 0.001
SecondaryNumber of Participants With ASAS Partial Remission

Participants were classified as having achieved ASAS partial remission if they had a value of less than 20 on a scale from 0 (normal/none) to 100 (most severe) in each of 4 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); and inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With ASAS Partial Remission
participantsAdalimumab/AdalimumabPlacebo/Adalimumab
Number of Participants With ASAS Partial Remission8533
SecondaryChange From Baseline in Patient Global Assessment of Disease Activity

Participants assessed their disease activity during the preceding week using a 100 millimeter (mm) visual analog scale, with responses ranging from no activity (0) to severe activity (100).

Time frame:
Baseline and Week 12
Reported as:
Mean · millimeters
Change From Baseline in Patient Global Assessment of Disease Activity
millimetersAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in Patient Global Assessment of Disease Activity-28.8 ± 24.16-11.7 ± 21.77
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · ANCOVA · p = < 0.001
SecondaryChange From Baseline in Patient Global Assessment of Disease Activity

Participants assessed their disease activity during the preceding week using a 100 millimeter (mm) visual analog scale, with responses ranging from no activity (0) to severe activity (100).

Time frame:
Baseline and Week 24
Reported as:
Mean · millimeters
Change From Baseline in Patient Global Assessment of Disease Activity
millimetersAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in Patient Global Assessment of Disease Activity-37.8 ± 24.47-35.5 ± 25.03
SecondaryChange From Baseline in Total Back Pain Score

Participants assessed their total back pain within the preceding week using a total back pain 100 mm visual analog scale, with responses ranging from no pain (0) to most severe pain (100).

Time frame:
Baseline and Week 12
Reported as:
Mean · millimeters
Change From Baseline in Total Back Pain Score
millimetersAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in Total Back Pain Score-32.0 ± 23.55-13.7 ± 22.88
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · Chi-squared, Corrected · p = < 0.001
SecondaryChange From Baseline in Total Back Pain Score

Participants assessed their total back pain within the preceding week using a total back pain 100 mm visual analog scale, with responses ranging from no pain (0) to most severe pain (100).

Time frame:
Baseline and Week 24
Reported as:
Mean · millimeters
Change From Baseline in Total Back Pain Score
millimetersAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in Total Back Pain Score-42.1 ± 23.29-37.8 ± 24.20
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score

Participants assessed their ability to perform 10 selected activities (e.g., putting on socks or tights without help or aids, bending forward from the waist to pick up a pen from the floor without an aid) during the preceding week. Responses ranged from 0 (easy) to 100 (impossible). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 100.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
units on a scaleAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score-17.5 ± 20.18-4.7 ± 16.40
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · ANCOVA · p = < 0.001
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score

Participants assessed their ability to perform 10 selected activities (e.g., putting on socks or tights without help or aids, bending forward from the waist to pick up a pen from the floor without an aid) during the preceding week. Responses ranged from 0 (easy) to 100 (impossible). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 100.

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
units on a scaleAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score-23.2 ± 21.03-20.9 ± 21.51
SecondaryChange From Baseline in Inflammation Score

The Inflammation score is the mean of the 10-cm visual analog scale scores from the 2 morning stiffness-related BASDAI questions: "How would you describe the overall level of morning stiffness you have had from the time you wake up?", with response ranging from none to very severe; and "How long does your morning stiffness last from the time you wake up?", with response ranging from 0 hours to 2 or more hours.

Time frame:
Baseline and Week 12
Reported as:
Mean · centimeters
Change From Baseline in Inflammation Score
centimetersAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in Inflammation Score-2.9 ± 2.01-1.5 ± 2.16
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · ANCOVA · p = < 0.001
SecondaryChange From Baseline in Inflammation Score

The Inflammation score is the mean of the 10-cm visual analog scale scores from the 2 morning stiffness-related BASDAI questions: "How would you describe the overall level of morning stiffness you have had from the time you wake up?", with response ranging from none to very severe; and "How long does your morning stiffness last from the time you wake up?", with response ranging from 0 hours to 2 or more hours.

Time frame:
Baseline and Week 24
Reported as:
Mean · centimeters
Change From Baseline in Inflammation Score
centimetersAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in Inflammation Score-3.6 ± 2.21-3.6 ± 2.24
SecondaryNumber of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria

A BASDAI50 responder had at least a 50% improvement from Baseline in BASDAI score. In the BASDAI, participants use a 10-centimeter visual analog scale to answer 6 questions pertaining to symptoms experienced in the preceding week (e.g., How would you describe the overall level of fatigue/tiredness you have experienced? How long does your morning stiffness last from the time you wake up?) Responses range from "none" to "very severe" or from 0 hours to 2 or more hours for morning stiffness. The score is calculated as 0.2 (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2).

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria
participantsAdalimumab/AdalimumabPlacebo/Adalimumab
Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria11419
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · Chi-squared · p = < 0.001
SecondaryNumber of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria

A BASDAI50 responder had at least a 50% improvement from Baseline in BASDAI score. In the BASDAI, participants use a 10-centimeter visual analog scale to answer 6 questions pertaining to symptoms experienced in the preceding week (e.g., How would you describe the overall level of fatigue/tiredness you have experienced? How long does your morning stiffness last from the time you wake up?) Responses range from "none" to "very severe" or from 0 hours to 2 or more hours for morning stiffness. The score is calculated as 0.2 (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2).

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria
participantsAdalimumab/AdalimumabPlacebo/Adalimumab
Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria15671
SecondaryChange From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)

Elevation of hs-CRP is a nonspecific marker of inflammation. Values above 5 milligrams/liter (mg/L) were considered abnormally high. Decrease in level of hs-CRP indicates reduction in inflammation.

Time frame:
Baseline and Week 12
Reported as:
Mean · milligrams/liter
Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)
milligrams/literAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)-17.8 ± 23.76-4.2 ± 21.23
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · ANCOVA · p = < 0.001
SecondaryChange From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)

Elevation of hs-CRP is a nonspecific marker of inflammation. Values above 5 milligrams/liter (mg/L) were considered abnormally high. Decrease in level of hs-CRP indicates reduction in inflammation.

Time frame:
Baseline and Week 24
Reported as:
Mean · milligrams/liter
Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)
milligrams/literAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)-18.2 ± 24.27-20.1 ± 30.63
SecondaryChange From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score

The SF-36 questionnaire, version 2, consists of 36 general health questions with 2 components, physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score
units on a scaleAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score6.6 ± 6.434.0 ± 6.31
Statistical analysis
  • Adalimumab/Adalimumab vs Placebo/Adalimumab · ANCOVA · p = < 0.001
SecondaryChange From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score

The SF-36 questionnaire, version 2, consists of 36 general health questions with 2 components, physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score
units on a scaleAdalimumab/AdalimumabPlacebo/Adalimumab
Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score8.6 ± 7.449.2 ± 7.25

Adverse events

Collected over All adverse events reported from the time of first study drug administration until 70 days following discontinuation of study drug administration were collected, for a maximum reporting period of 32 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab (Period 1)—1/229 (0.4%)55/229 (24%)
Placebo (Period 1)—1/115 (0.9%)16/115 (13.9%)
Adalimumab/Adalimumab (Period 2)—3/224 (1.3%)32/224 (14.3%)
Placebo/Adalimumab (Period 2)—1/113 (0.9%)22/113 (19.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventAdalimumab (Period 1)Placebo (Period 1)Adalimumab/Adalimumab (Period 2)Placebo/Adalimumab (Period 2)
Hepatitis viralInfections and infestations0/2290/1150/2241/113
Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2291/1150/2240/113
Intraductal papilloma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2291/1150/2240/113
Peritoneal tuberculosisInfections and infestations0/2290/1151/2240/113
Pulmonary tuberculosisInfections and infestations0/2290/1151/2240/113
Tuberculosis pleurisyInfections and infestations0/2290/1151/2240/113
ConcussionInjury, poisoning and procedural complications0/2290/1151/2240/113
ContusionInjury, poisoning and procedural complications0/2290/1151/2240/113
Skin lacerationInjury, poisoning and procedural complications0/2290/1151/2240/113
Abortion inducedSurgical and medical procedures0/2290/1151/2240/113
Most frequent other events
Showing 10 of 15
Most frequent other events
EventAdalimumab (Period 1)Placebo (Period 1)Adalimumab/Adalimumab (Period 2)Placebo/Adalimumab (Period 2)
Alanine aminotransferase increasedInvestigations26/2292/11511/22413/113
Aspartate aminotransferase increasedInvestigations20/2291/1156/2249/113
Upper respiratory tract infectionInfections and infestations13/2299/11513/2248/113
White blood cell count decreasedInvestigations6/2292/1152/2241/113
Blood bilirubin increasedInvestigations0/2290/1154/2240/113
Platelet count decreasedInvestigations2/2290/1154/2240/113
Injection site swellingGeneral disorders1/2290/1150/2242/113
Blood alkaline phosphatase increasedInvestigations3/2290/1150/2242/113
Blood triglycerides increasedInvestigations3/2291/1152/2242/113
Injection site erythemaGeneral disorders4/2290/1150/2241/113

Baseline characteristics

Age Continuous
Age Continuous(years)AdalimumabPlaceboTotal
Mean30.1 ± 8.7329.6 ± 7.4929.9 ± 8.33
Sex: Female, Male
Sex: Female, Male(Participants)AdalimumabPlaceboTotal
Female442064
Male18595280
Region of Enrollment
Region of Enrollment(participants)AdalimumabPlaceboTotal
China229115344
08

Study locations

9 sites
  • Site Reference ID/Investigator# 24054
    Hefei, Anhui 230022, China
  • Site Reference ID/Investigator# 25522
    Beijing, 100029, China
  • Site Reference ID/Investigator# 24055
    Beijing, 100032, China
  • Site Reference ID/Investigator# 24052
    Beijing, 100853, China
  • Site Reference ID/Investigator# 24056
    Guangzhou, 510630, China
  • Site Reference ID/Investigator# 24243
    Hangzhou, 310009, China
  • Site Reference ID/Investigator# 24053
    Shanghai, 200001, China
  • Site Reference ID/Investigator# 24058
    Shanghai, 200003, China
  • Site Reference ID/Investigator# 24057
    Xi'an, 710032, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Sep 2010 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2010
First posted
May 3, 2010
Start
Jan 2010
Primary completionActual
Sep 2010
CompletionActual
Feb 2011
Results first posted
Nov 4, 2011
Last update
Dec 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01114880
Lead sponsor
Abbott
Responsible party
Sponsor
First posted
May 3, 2010
Start date
Jan 2010
Primary completion
Sep 2010
Completion
Feb 2011
Results posted
Nov 4, 2011
Last update
Dec 1, 2011

Study contacts

Aileen Pangan
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion